Nawal OUZREN

Company: SENSORION

Job title: CEO

Seminars:

Panel Discussion & Live Audience Q&A: Is 2025 the Year of Curing Deafness? Reviewing Past Failures, Recent Successes & Future Opportunities for Inner Ear Disorders Therapeutics 8:00 am

Discussing the back-to-back positive results for gene therapies, large investments from key pharma into the inner ear disorders field, and uncovering the opportunities for 2024 and 2025 Leveraging lessons from past failures and understanding their downfalls Understanding the current challenges with novel targets, preclinical models replicating the inner ear structures, less invasive delivery mechanisms and…Read more

day: Conference Day 1

Exploring Clinically Validated Non-Invasive Oral Therapy to Preserve Residual Hearing After Cochlear Implantation 2:30 pm

Explore first-in-class oral drug candidates for hearing preservation postimplantation with minimal side effects, reduced auditory deficit and improved recovery Oral drug concentrations in the perilymph signifies a significant leap in understanding drug distribution dynamics, offering insights crucial for optimizing therapeutic efficacy in inner ear disorders Achieving primary endpoints for residual hearing preservation in the perilymph,…Read more

day: Conference Day 2